Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4% – Should You Sell?

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) traded down 4% during trading on Monday . The company traded as low as $3.52 and last traded at $3.57. 254,081 shares were traded during mid-day trading, a decline of 18% from the average session volume of 309,497 shares. The stock had previously closed at $3.72.

Analyst Ratings Changes

A number of analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Price Performance

The firm has a market cap of $73.65 million, a PE ratio of -1.27 and a beta of 1.63. The firm has a 50-day simple moving average of $4.87 and a 200 day simple moving average of $3.32.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oppenheimer & Co. Inc. increased its holdings in shares of Protara Therapeutics by 40.8% during the third quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after acquiring an additional 51,944 shares in the last quarter. XTX Topco Ltd bought a new stake in Protara Therapeutics in the 3rd quarter worth about $60,000. Geode Capital Management LLC increased its holdings in Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after buying an additional 29,514 shares in the last quarter. Bailard Inc. bought a new stake in Protara Therapeutics in the 4th quarter worth about $157,000. Finally, Commonwealth Equity Services LLC increased its holdings in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock worth $195,000 after buying an additional 17,572 shares in the last quarter. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.